SEARCH OUR PAGES

Products

Products

Our pipeline
Delivering first-in-class immunotherapies
of activation and regulation

OSE Immunotherapeutics’ team has unique expertise and experience in immunological target discovery that serves as the basis for the development of innovative agonists and antagonists for application in immuno-oncology and autoimmune diseases.

OSE Immunotherapeutics has a balanced clinical and preclinical portfolio of products with a diversified risk profile.

OSE Immunotherapeutics’ R&D expertise in immunology has translated into several first-in-class products that activate or regulate the immune system and are being developed in a wide range of clinical indications. Its approach has been validated through partnerships with academic institutions and leading global pharmaceutical companies.

Three areas of expertise are being developed within our immunology research platform:

  • T-cell-based vaccination
  • Immuno-oncology (focus on myeloid targets)
  • Auto-immunity & Inflammation

OSE Immunotherapeutics has a proven ability to deliver novel therapeutic products from target identification to clinical outcomes:

  • Phase 3 asset (Tedopi®) with positive final results of the trial Atalante in patients with non-small cell lung cancer after secondary resistance to checkpoint inhibitors.
  • 5 clinical stage assets in immuno-oncology and auto-immunity.
  • 1 second generation COVID-19 prophylactic vaccine program (CoVepiT) in Phase 1 clinical trial – Voluntary and temporary pause of enrollment ongoing.

Endorsed by significant partnerships with Servier, Boehringer Ingelheim and Veloxis Pharmaceuticals for up to €1.6Bn in milestones (€72 M already received since 2016)

Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Vaccines
Tedopi®
Neoepitopes
NSCLC post ICI failure
Final positive results presented at the ESMO 2021
Tedopi®
Neoepitopes
Pancreatic cancer
Ongoing
Tedopi®
Neoepitopes
Ovarian cancer
In combo with Keytruda®
Tedopi®
Neoepitopes
NSCLC after first-line chemo-immunotherapy
In combo with Opdivo®
CoVepiT
Optimized epitopes of SARS-CoV-2
COVID-19 vaccine
Ongoing

Platform

  • Target Modality Neoepitopes
  • Indication NSCLC post ICI failure
  • Pre-Clinical POC
  • Phase 1
  • Phase 2
  • Phase 3 Final positive results presented at the ESMO 2021
  • Partners
  • Target Modality Neoepitopes
  • Indication Pancreatic cancer
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 Ongoing
  • Phase 3
  • Partners
  • Target Modality Neoepitopes
  • Indication Ovarian cancer
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 In combo with Keytruda®
  • Phase 3
  • Partners
  • Target Modality Neoepitopes
  • Indication NSCLC after first-line chemo-immunotherapy
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 In combo with Opdivo®
  • Phase 3
  • Partners
  • Target Modality Optimized epitopes of SARS-CoV-2
  • Indication COVID-19 vaccine
  • Pre-Clinical POC
  • Phase 1 Ongoing
  • Phase 2
  • Phase 3
  • Partners
Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Immuno-Oncology
BI 765063 (OSE-172)
CD47/SIRPa Antagonist
Advanced solid tumours
Ongoing
CLEC-1
"Don't Eat Me" signal - Myeloid checkpoint
Various cancers
Ongoing
BiCKI®
T Cells + Innovative targets
Various cancers
Ongoing

Platform

  • Target Modality CD47/SIRPa Antagonist
  • Indication Advanced solid tumours
  • Pre-Clinical POC
  • Phase 1 Ongoing
  • Phase 2
  • Phase 3
  • Partners
  • Target Modality "Don't Eat Me" signal - Myeloid checkpoint
  • Indication Various cancers
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
  • Target Modality T Cells + Innovative targets
  • Indication Various cancers
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners
Platform
Target/Modality
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Partners
Auto-Immunity & Inflammation
OSE-127
IL7-R Antagonist
UC; Sjögren
On-going in UC and in Sjögren
FR104
CD28 Antagonist
Auto-immune diseases & Transplantation
Tx (Veloxis): Phase 1 status
AID: Phase 2 status
OSE-230
Anti-ChemR23 Agonist
Resolution of inflammation
Ongoing

Platform

  • Target Modality IL7-R Antagonist
  • Indication UC; Sjögren
  • Pre-Clinical POC
  • Phase 1
  • Phase 2 On-going in UC and in Sjögren
  • Phase 3
  • Partners
  • Target Modality CD28 Antagonist
  • Indication Auto-immune diseases & Transplantation
  • Pre-Clinical POC
  • Phase 1 Tx (Veloxis): Phase 1 status
  • Phase 2 AID: Phase 2 status
  • Phase 3
  • Partners
  • Target Modality Anti-ChemR23 Agonist
  • Indication Resolution of inflammation
  • Pre-Clinical POC Ongoing
  • Phase 1
  • Phase 2
  • Phase 3
  • Partners